about
Breast cancer screening: are we seeing the benefit?Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy.Balancing harms and benefits of service mammography screening programs: a cohort study.Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997-2001)Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction.Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.Misclassification of breast cancer as cause of death in a service screening area.The other side of technology: risk of overdiagnosis of breast cancer with mammography screening.Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review.European breast cancer service screening outcomes: a first balance sheet of the benefits and harms.Colorectal cancer mortality in two areas of Tuscany with different screening exposures.Patterns and determinants of receipt of follow-up mammography and/or clinical examination in a cohort of Italian breast cancer survivors.A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis.Breast screening: axillary lymph node status of interval cancers by interval year.Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix.Overdiagnosis in breast cancer: design and methods of estimation in observational studies.Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?A simple method to estimate the episode and programme sensitivity of breast cancer screening programmes.Effectiveness of service screening: a case–control study to assess breast cancer mortality reduction.An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence.Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.Minor influence of self-selection bias on the effectiveness of breast cancer screening in case-control studies in the Netherlands.Lower mother-to-child HIV-1 transmission in boys is independent of type of delivery and antiretroviral prophylaxis: the Italian Register for HIV Infection in Children.Breast cancer screening case-control study design: impact on breast cancer mortality.Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort studyDoes an organised screening programme reduce the inequalities in breast cancer survival?Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening SettingReproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting
P50
Q31096711-A9B64043-0D1E-4D86-BC1F-AB07FDEC0CB5Q34041688-FC9E25B1-0429-4164-B0BF-DFC9096A2787Q35066980-2769739E-E006-4CB0-9B14-712D0BC91A58Q35633665-BC6B930D-5C84-4110-88D4-830AE0BA37D4Q36393116-D3DB1176-FD35-4CD6-A9EF-673674A28416Q36611927-F83A4EE8-523D-4D07-BA58-3BF686941FAAQ36858064-06B754FE-8B36-465F-B12D-32178C16AB90Q37109441-15366A10-D894-4785-9449-3AA4A7CE663AQ37171140-5C157DF1-EFA7-4D73-B11F-4797F9808173Q37328053-4AA2C272-E50C-4BE9-AC2C-EC50D953CA8BQ37486773-FD64ACA8-77B6-40B4-8E34-2ED4D1B64325Q38042897-1DBF66E6-30AC-406B-8BEA-9C0D38B10774Q38225849-50F5E35F-A1E5-483B-97AF-8CFEDFDCC23CQ38452884-AFE7796F-FFAB-40C6-B1EE-2FD4B30E20C9Q40660635-84432335-2F1B-4894-B0DE-83FE165B6239Q41683942-941249A6-DA45-42AA-94BE-DA61D364FDADQ43791052-DBDFE023-8B2D-412E-AFD0-B3D000BE33A8Q43822277-0CA3D281-77C5-4E58-9876-9B24BFBB2DE7Q44119126-E8248F53-4543-4F0D-973F-7E47C725BE9EQ44596742-375F72C1-4DF6-40D3-BBF8-023C188602FFQ44990021-AC33FCA5-0FD7-41F1-A9A4-FD5B4B595723Q45063666-417A2B2E-AC98-44E5-ABE3-CA85D400085AQ45755989-42A2D9C1-9525-412B-BBEA-BE9241FA4771Q45762231-3857C0D2-DCEE-4B4C-942B-8A1ED14996DDQ45847753-BB5DFAFC-2E01-4DA2-8430-28FC98AED88BQ48556136-873F31E6-361B-43C7-AAF5-9EB8178CF9FDQ52994873-AADC7C5C-99EF-4BF5-B80B-D854F0B638C4Q53074862-12A73D62-D7BC-416D-9C15-17FA93FE6AB0Q58793591-FA24652B-2184-4FB6-BB35-4AFAD31EACF8Q63966440-BADF5538-95CD-42E9-939F-23614834F344Q63966441-EA937B41-AC00-4ABC-944E-7E4201235890Q81306581-60364D2A-B2D4-41DD-B59F-DEC31650B53A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Donella Puliti
@ast
Donella Puliti
@en
Donella Puliti
@es
Donella Puliti
@nl
type
label
Donella Puliti
@ast
Donella Puliti
@en
Donella Puliti
@es
Donella Puliti
@nl
prefLabel
Donella Puliti
@ast
Donella Puliti
@en
Donella Puliti
@es
Donella Puliti
@nl
P106
P1153
23028770100
P21
P31
P496
0000-0002-3820-4442